Simultaneous arming and structure/activity studies of natural products employing O-H insertions: An expedient and versatile strategy for natural products-based chemical genetics

Journal of the American Chemical Society

Volumn 129, Issue 40, 2007, Pages 12222-12231

  Peddibhotla, Satyamaheshwar ^a   Dang, Yongjun ^b   Liu, Jun O ^b   Romo, Daniel ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL GENETICS; MONOFUNCTIONALIZATION; NATURAL PRODUCTS;

GENES; GENETIC ENGINEERING; PROTEINS; REACTION KINETICS;

MOLECULAR STRUCTURE;

ACETIC ACID DERIVATIVE; ALCOHOL; ALKYNE DERIVATIVE; ALKYNYL GROUP; BINDING PROTEIN; BIOTIN DERIVATIVE; BREFELDIN A; CALCINEURIN; CALCINEURIN A; CALCINEURIN B; CALMODULIN; EPHEDRINE; ESTRADIOL; FUNCTIONAL GROUP; GIBBERELLIC ACID; GIBBERELLIC ACID METHYL ESTER; IMMUNOSUPPRESSIVE AGENT; NATURAL PRODUCT; PACLITAXEL; PROTEIN FKBP12; RHODIUM; TACROLIMUS; UNCLASSIFIED DRUG; YOHIMBINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYST; CHEMICAL GENETICS; COMPLEX FORMATION; CONJUGATE; CONJUGATION; CYCLOADDITION; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ALCOHOLS; ALKYNES; BIOLOGICAL PRODUCTS; BIOTIN; BREFELDIN A; CYCLIZATION; ESTERS; FORMIC ACID ESTERS; GIBBERELLINS; HELA CELLS; HUMANS; JURKAT CELLS; ORGANOMETALLIC COMPOUNDS; PHARMACEUTICAL PREPARATIONS; RHODIUM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TACROLIMUS;

EID: 35048856423     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0733686     Document Type: Article

References (91)

1. Hopkins, A. L.; Groom, C. R. Nat. Rev. 2002, 1, 727-730.
2. Meisner, N.-C.; Hintersteiner, M.; Uhl, V.; Weidemann, T.; Schmied, M.; Gstach, H.; Auer, M. Curr. Opin. Chem. Biol. 2004, 8, 424-431.
3. Clardy, J.; Walsh, C. Nature 2004, 432, 829-837.
4. Feher, M.; Schmidt, J. M. J. Chem. Inf. Comput. Sci. 2003, 43, 218-227.
5. (a) Paterson, I.; Anderson, E. A. Science 2005, 310, 451-453.
6. (b) Koehn, F. E.; Carter, G. T. Nat. Rev. Drug Discovery 2005, 4, 206-220.
7. Strausberg, R. L.; Schreiber, S. L. Science 2003, 300, 294-295.
8. For a review, see: (a) Piggott, A. M.; Karuso, P. Comb. Chem. High Throughput Screening 2004, 7, 607-630.
9. For more recent examples, see: (b) Statsuk, A. V.; Bai, R.; Baryza, J. L.; Verma, V. A.; Hamel, E.; Wender, P. A.; Kozmin, S. A. Nat. Chem. Biol. 2005, 1, 383-388.
10. (c) Low, W.-K.; Dang, Y.; Schneider-Poetsch, T.; Shi, Z.; Choi, N. S.; Merrick, W. C.; Romo, D.; Liu, J. O. Mol. Cells 2005, 20, 709-722.
11. (d) Yamaoka, M.; Sato, K.; Kobayashi, M.; Nishio, N.; Ohkubo, M.; Fujii, T.; Nakajima, H. J. Antibiot. 2005, 58, 654-662.
12. (e) Muddana, S. S.; Peterson, B. R. Org. Lett. 2004, 6, 1209-1212.
13. (f) Nyangulu, J. M.; Galka, M. M.; Jadhav, A.; Gai, Y.; Graham, C. M.; Nelson, K. M.; Cutler, A. J.; Taylor, D. C.; Banowetz, G. M.; Abrams, S. R. J. Am. Chem. Soc. 2005, 127, 1662-1664.
14. (g) Zumbuehl, A.; Jeannerat, D.; Martin, S. E.; Sohrmann, M.; Stano, P.; Vigassy, T.; Clark, D. D.; Hussey, S. L.; Peter, M.; Peterson, B. R.; Pretsch, E.; Walde, P.; Carreira, E. M. Angew. Chem, Int. Ed. 2004, 43, 5181-5185.
15. Clardy, J. ACS Chem. Biol. 2006, 1, 17-19.
16. Kanoh, N.; Honda, K.; Simizu, S.; Muroi, M.; Osada, H. Angew. Chem. Int. Ed. 2005, 44, 3559-3562.
17. The term chemoselectivity is used to describe reactions that discriminate between two functional group types in a given molecule. Site selectivity has been utilized to describe selective reaction at one position in a natural product (see ref 11) or one amino acid of a protein over another but it does not inherently imply chemoselective. Therefore, we propose use of the term "chemosite selective" to describe a reaction that exhibits both chemo and site selectivity.
18. For a recent example of minimal peptide-mediated acylation of erythromycin aglycone, see: (a) Lewis, C. A.; Miller, S. J. Angew. Chem. Int. Ed. 2006, 45, 5616-5619.
19. This article, which appeared when our work was in progress, adequately describes the concept of "double diastereodifferentiation" employing chiral peptide catalysts and natural products. For examples of glycorandomization of natural products, see: (b) Thibodeaux, C. J.; Melancon, C. E.; Liu, H.-W. Nature 2007, 446, 1008-1016.
20. (c) Minami, A.; Eguchi, T. J. Am. Chem. Soc. 2007, 129, 5102-5107.
21. (d) Zhang, C.; Griffith, B. R.; Fu, Q.; Albermann, C.; Fu, X.; Lee, I.-K.; Li, L.; Thorson, J. S. Science 2006, 313, 1291-1294 and references therein.
22. (e) Yang, M.; Proctor, M. R.; Bolam, D. N.; Errey, J. C.; Field, R. A.; Gilbert, H. J.; Davis, B. G. J. Am. Chem. Soc. 2005, 127, 9336-9337.
23. (f) Minami, A.; Uchida, R.; Eguchi, T.; Kakinuma, K. J. Am. Chem. Soc. 2005, 127, 6148-6149.
24. For examples of prenylation of natural products, see: (g) Kuzuyama, T.; Noel, J. P.; Richard, S. B. Nature 2005, 435, 983-987.
25. (h) Cui, G.; Li, X.; Merz, K. M., Jr. Biochemistry 2007, 46, 1303-1311.
26. (a) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem. Int. Ed. 2002, 41, 2596-2599.
27. For mechanistic studies of this cycloaddition, see: (b) Bock, V. D.; Hiemstra, H.; van Maarseveen, J. H. Eur. J. Org. Chem. 2005, 1, 51-68.
28. (c) Torne, C. W.; Christensen, C.; Meldal, M. J. Org, Chem. 2002, 67, 3057-3064.
29. Huisgen, R.; Szeimies, G.; Moebius, L. Chem. Ber. 1967, 100, 2494-2507.
30. Henkel, T.; Brunne, R. M.; Müller, H.; Reichel, F. Angew. Chem. Int. Ed. 1999, 38, 643-647.
31. For some representative mild methods for derivatization of alcohols in natural products, see: (a) Stewart, I. C.; Bergman, R. G.; Toste, F. D. J. Am. Chem. Soc. 2003, 125, 8696-8697.
32. (b) Petchprayoon, C.; Suwanborirux, K.; Miller, R.; Sakata, T.; Marriott, G. J. Nat. Prod. 2005, 68, 157-161.
33. (c) de Blas, J.; Dominguez, E.; Ezquerra, J. Tetrahedron Lett. 2000, 41, 4567-4571.
34. (d) Khan, A. T.; Choudhury, L. H.; Ghosh, S. Tetrahedron Lett. 2004, 45, 7891-7894.
35. (e) Miller, D. J.; Moody, C. J. Tetrahedron 1995, 51, 10811-10843.
36. (f) Milioni, C.; Jung, L.; Koch, B. Eur. J. Med. Chem. 1991, 26, 947-951.
37. (g) Liljeblad, A.; Aksela, R.; Kanerva, L. T. Tetrahedron: Asymmetry 2000, 41, 4567-4571.
38. Khmelnitsky, Y. L.; Budde, C.; Arnold, J. M.; Usyatinsky, A.; Clark, D. S.; Dordick, J. S. J. Am. Chem. Soc. 1997, 119, 11554-11555.
39. For a comprehensive overview, see: Doyle, M. P.; McKervey, M. A.; Ye, T. Modern Catalytic Methods for Organic Synthesis with Diazo Compounds; Wiley: New York, 1998.
40. Paulissen, R.; Reimlinger, H.; Hayez, E.; Hubert, A. J.; Teyssié, Ph. Tetrahedron Lett. 1973, 24, 2233-2236.
41. For a review, see: Cox, G. G.; Miller, D. J.; Moody, C. J.; Sie, E.-R. H. B.; Kulagowski, J. J. Tetrahedron 1995, 51, 10811-10843.
42. Cox, G. G.; Kulagowski, J. J.; Moody, C. J.; Sie, E.-R. H. B. Synlett 1992, 51, 975-976.
43. Davies, H. M. L.; Beckwith, R. E. J. Chem. Rev. 2003, 103, 2861-2903.
44. Doyle, M. P. J. Org. Chem. 2006, 71, 9253-9260.
45. Maier, T. C.; Fu, G. C. J. Am. Chem. Soc. 2006, 128, 4594-4595.
46. For details regarding the preparation of alkynyl diazo esters utilized in this study, see Supporting Information.
47. For an excellent review on donor- and acceptor-substituted carbenoids, see: Davies, H. M. L.; Nikolai, J. Org. Biomol. Chem. 2005, 3, 4176-4187.
48. Lu, C.-D.; Liu, H.; Chen, Z.-Y.; Hu, W.-H.; Mi, A.-Q. Org. Lett. 2005, 7, 83-86.
49. Drahl, C.; Cravatt, B. F.; Sorensen, E. J. Angew. Chem. Int. Ed. 2005, 44, 5788-5809.
50. (a) Shimkus, M.; Levy, J.; Herman, T. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2593-2597.
51. (b) Speers, A. E.; Cravatt, B. F. J. Am. Chem. Soc. 2005, 127, 10018-10019.
52. (c) Gartner, C. A.; Elias, J. E.; Bakalarski, C. E.; Gygi, S. P. J. Proteome Res. 2007, 6, 1482-1491.
53. Hydrolysis experiments were performed with a simple model ester i to determine the stability of the bromobenzyl acetate esters. Complete hydrolysis of ester i required a pH = 13 at 22°C in 48 h and delivered the bromobenzylacetic acid ii. See Supporting Information for details. (Chemical Equation Presented)
54. Cox, G. G.; Haigh, D.; Hindley, R. M.; Miller, D. J.; Moody, C. J. Tetrahedron Lett. 1994, 35, 3139-3142.
55. (a) Srivastava, V.; Tandon, A.; Ray, S. Synth. Commun. 1992, 22, 2703-2710.
56. (b) Yamada, S. Tetrahedron Lett. 1992, 33, 2171-2174.
57. (a) Anadu, N. O.; Davisson, V. J.; Cushman, M. J. Med. Chem. 2006, 49, 3897-3905.
58. (b) Zhu, J.-W.; Nagasawa, H.; Nagura, F.; Mohammad, S. B.; Uto, Y.; Ohkura, K.; Hori, H. Bioorg. Med. Chem. Lett. 2000, 8, 455-463.
59. (a) Luo, Y.; Prestwich, G. D. Bioconjugate Chem. 1999, 10, 755-763.
60. (b) Chenu, J.; Tokoudju, M.; Wright, M.; Senilh, V.; Guenard, D. J. Labelled Compd. Radiopharm. 1987, 24, 1245-1255.
61. (c) Mathew, A. E.; Mejillano, M. R.; Nath, J. P.; Hirnes, R. H.; Stella, V. J. J. Med. Chem. 1992, 35, 145-151.
62. See Supporting Information for details.
63. (a) Hersperger, R.; Buchheit, K.-H.; Cammisuli, S.; Enz, A.; Lohse, O.; Ponelle, M.; Schuler, W.; Schweitzer, A.; Walker, C.; Zehender, H.; Zenke, G.; Zimmerlin, A. G.; Zollinger, M.; Mazzoni, L.; Fozard, J. R. J. Med. Chem. 2004, 47, 4950-4957.
64. J. Med. Chem. 2004, 47, 4950-4957.
65. (b) Fretz, H.; Albers, M. W.; Galat, A.; Standaert, R. F.; Lane, W. S.; Burakoff, S. J.; Bierer, B. E.; Schreiber, S. L. J. Am. Chem. Soc. 1991, 113, 1409-1411.
66. Gu, J.; Ruppen, M. E.; Cai, P. Org. Lett. 2005, 7, 3945-3948.
67. Espino, C. G.; Fiori, K. W.; Kim, M.; DuBois, J. J. Am. Chem. Soc. 2004, 126, 15378-15379.
68. Fructos, M. R.; Belderrain, T. R.; Nicasio, M. C.; Nolan, S. P.; Kaur, H.; Díaz-Requejo, M. M.; Pérez, P. J. J. Am. Chem. Soc. 2004, 126, 10846-10847.
69. For pull-down of FK506 binding proteins with resin beads, see: (a) Mori, T.; Takahashi, T.; Shiyama, T.; Tanaka, A.; Hira, N.; Tanaka, N.; Hosoya, K. Bioorg. Med. Chem. 2006, 14, 5549-5554 and references therein.
70. Employing Affigel, see: (b) Reference 35b.
71. (c) Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. Nature 1989, 341, 758-760.
72. By the yeast three-hybrid system using an FK506-biotin conjugate, see: (d) de Felipe, K.; Carter, B. T.; Althoff, E. A.; Cornish, V. W. Biochemistry 2004, 43, 10353-10363.
73. (e) Licitra, E. J.; Liu, J. O. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 12817-128121.
74. By phage display with an FK506-biotin conjugate, see: (f) Sche, P. P.; Mckenzie, K. M.; White, J. D.; Austin, D. J. Chem. Biol. 1999, 6, 707-716.
75. By photo-cross-linking to modified agarose, see: (g) Kanoh, N.; Honda, K.; Simizu, S.; Muroi, M.; Osada, H. Angew. Chem. Int. Ed. 2005, 44, 3559-3562.
76. By reverse affinity beads with immobilized FKBP, see: (h) Ohtsu, Y.; Ohba, R.; Imamura, Y.; Kobayashi, M.; Hatori, H.; Zenkoh, T.; Hatakeyama, M.; Manabe, T.; Hino, M.; Yamaguchi, Y.; Kataoka, K.; Kawaguchi, H.; Watanabe, H.; Handa, H. Anal. Biochem. 2005, 338, 245-252.
77. By use of radio-labelled FK506, see: (i) Palaszynski, E. W.; Donnelly, J. G.; Soldin, S. J. Clin. Biochem. 1991, 24, 63-70.
78. Wagner, R.; Rhoades, T. A.; Or, Y. S.; Lane, B. C.; Hsieh, G.; Mollison, K. W.; Luly, J. R. J. Med. Chem. 1998, 41, 1764-1776.
79. Liu, J.; Farmer, J. D., Jr.; Lane, W. S.; Friedman, J.; Weissman, I.; Schreiber, S. L. Cell 1991, 66, 807-815.
80. While our work was in progress, a similar observation using a hydrophilic polymer-immobilized FK506 was reported. See: Takahashi, T.; Shiyama, T.; Mori, T.; Hosoya, K.; Tanaka, A. Anal. Bioanal. Chem. 2006, 385, 122-127.
81. Siekierka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. Nature 1989, 341, 755-757.
82. Becker, J. W.; Rotonda, J.; Cryan, J. G.; Martin, M.; Parsons, W. H.; Sinclair, P. J.; Wiederrecht, G.; Wong, F. J. Med. Chem. 1999, 42, 2798-2804.
83. (a) Singleton, V. L.; Bohonos, N.; Ullstrup, A. J. Nature 1958, 181, 1072-1073.
84. (b) Kim, H. L.; Kochevar, J. Gen. Pharmacol. 1995, 26, 363-364.
85. Klausner, R. D.; Donaldson, J. G.; Lippincott-Schwartz, J. J. Cell Biol. 1992, 116, 1071-1080.
86. The cyclopentyl alcohol (C13) has previously been shown to be the most readily functionalized. See ref 32.
87. Ishii, S.; Nagasawa, M.; Kariya, Y.; Yamamoto, H. J. Antibiot. 1989, 42, 1877-1878.
88. (a) Shao, R. G.; Shimizu, T.; Pommier, Y. Exp. Cell Res. 1996, 227, 190-196.
89. (b) Hacki, J.; Egger, L.; Monney, L.; Conus, S.; Rosse, T.; Fellay, I.; Borner, C. Oncogene 2000, 19, 2286-2295.
90. (c) Rao, R. V.; Castro-Obregon, S.; Frankowski, H.; Schuler, M.; Stoka, V.; del Rio, G.; Bredesen, D. E.; Ellerby, H. M. J. Biol. Chem. 2002, 277, 21836-21842.
91. Guo, H.; Tittle, T. V.; Allen, H.; Maziarz, R. T. Exp. Cell Res. 1998, 245, 57-68.